ArticleCancer cell international2025
DAPK1 identified as a novel biomarker for colorectal cancer liver metastasis.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLiver metastasis is the leading cause of mortality in colorectal cancer (CRC) patients, and there is an urgent need for biomarkers to improve the diagnosis and prognosis of CRC. However, the molecular mechanisms driving metastatic progression remain incompletely understood, necessitating the discovery of novel therapeutic targets.
methodsGEO datasets and machine learning algorithms (Lasso regression, SVM, and RF) were employed to screen for upregulated genes in CRC liver metastasis. Protein-protein interaction (PPI) networks were constructed using STRING. Single-cell RNA sequencing (scRNA-seq) and ATAC-seq were performed to analyze immune infiltration and chromatin accessibility in metastatic tissues. Functional enrichment analysis of RNA-seq data was conducted to explore DAPK1-related pathways. Finally, CRISPR/Cas9-mediated knockout of DAPK1 in LoVo cells was used to validate its role in invasion and migration.
resultsIn this study, we identified DAPK1 as a metastasis-specific upregulated gene in CRC. scRNA-seq of CRC metastases highlighted a significant correlation between DAPK1 expression and macrophage infiltration. Furthermore, ATAC-seq analysis demonstrated increased chromatin accessibility of DAPK1 in CRC liver metastasis. CRISPR/Cas9-mediated knockout of DAPK1 in LoVo cells markedly suppressed their invasion and migration.
conclusionsBy combining machine learning and multi-omics bioinformatics approaches, we identified DAPK1 as a novel biomarker for CRC liver metastasis, which has potential implications for prognosis and therapeutic targeting. These findings highlight DAPK1 as a critical driver of metastatic progression and provide a theoretical foundation for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.